Skip to main content
SearchLoginLogin or Signup

Reviews of "A Natural Broad-spectrum Inhibitor of Enveloped Virus Entry, Effective Against SARS-CoV-2 and Influenza A Virus in Preclinical Animal Models"

Reviewer: W Zhang (Northwestern University) | 📗📗📗📗◻️

Published onAug 02, 2022
Reviews of "A Natural Broad-spectrum Inhibitor of Enveloped Virus Entry, Effective Against SARS-CoV-2 and Influenza A Virus in Preclinical Animal Models"
key-enterThis Pub is a Review of
A natural broad-spectrum inhibitor of enveloped virus entry, effective against SARS-CoV-2 and Influenza A Virus in preclinical animal models
Description

SummaryThe COVID-19 pandemic has highlighted the need for novel antivirals for pandemic management and preparedness. Targeting host processes that are co-opted by viruses is an attractive strategy for developing antivirals with a high resistance barrier. Picolinic acid (PA) is a byproduct of tryptophan metabolism, endogenously produced in humans and other mammals. Here we report broad-spectrum antiviral effects of PA against enveloped viruses, including Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), Influenza A virus (IAV), Flaviviruses, Herpes Simplex Virus, and Human Parainfluenza Virus. We further demonstrate using animal models that PA is effective against SARS-CoV-2 and IAV, especially as an oral prophylactic. The mode of action studies revealed that PA inhibits viral entry of enveloped viruses, primarily by interfering with viral-cellular membrane fusion, inhibiting virus-mediated syncytia formation, and dysregulating cellular endocytosis. Overall, our data establish PA as a broad-spectrum antiviral agent, with promising preclinical efficacy against pandemic viruses SARS-CoV-2 and IAV.

To read the original manuscript, click the link above.

Reviewer 1 (Wei Z…) | 📗📗📗📗◻️

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below. 


Comments
0
comment

No comments here

Why not start the discussion?